Lantheus 
Welcome,         Profile    Billing    Logout  
 8 Products   15 Diseases  8 Products   50 Trials   3642 News 
62 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
2020-001996-33: A Phase 2b/3 Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Not yet recruiting
3
290
Europe
Leronlimab(PRO 140), Injection, Leronlimab Injection 175mg/ml (PRO-140)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019 (COVID-19), Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT02859961: Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection

Completed
2/3
556
US
PRO 140 (350 mg), Leronlimab, PRO 140 (525 mg), PRO 140 (700 mg)
CytoDyn, Inc.
HIV
09/20
12/20
NCT02990858: An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

Active, not recruiting
2/3
44
NA
PRO 140 SC injections
CytoDyn, Inc.
Hiv, Human Immunodeficiency Virus
06/22
08/22
NCT03902522: PRO 140 in Treatment-Experienced HIV-1 Subjects

Active, not recruiting
2/3
25
US
PRO 140, Leronlimab
CytoDyn, Inc.
HIV-1-infection
07/22
08/22
PRO 140_CD03 Extension, NCT05271370: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Active, not recruiting
2/3
56
US
PRO 140 350, PRO 140 525, PRO 140 700
CytoDyn, Inc.
HIV-1-infection
12/22
04/23
NCT04347239 / 2020-001996-33: Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Active, not recruiting
2b
394
US
Placebos, Leronlimab (700mg)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019
10/21
06/22
NCT04504942: Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
2
30
US
Leronlimab
CytoDyn, Inc., Amarex Clinical Research
Solid Tumor, Adult
11/21
07/22
NCT04521114: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Completed
2
87
US
Placebo, leronlimab 700 mg, PRO 140, leronlimab 350 mg
CytoDyn, Inc., Amarex Clinical Research
Nonalcoholic Steatohepatitis (NASH)
12/21
12/21
NCT02355184: An Extension of Protocol PRO 140_CD01 TS Study

Active, not recruiting
2
28
US
PRO 140 350mg weekly SQ injection., PRO 140
CytoDyn, Inc.
HIV, Human Immunodeficiency Virus
06/22
08/22
NCT05730673: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Withdrawn
2
NA
700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2, 160 mg Regorafenib at week 3
CytoDyn, Inc., Amarex Clinical Research
CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer
05/23
08/23
NCT06699836: A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Recruiting
2
60
US
350 mg leronlimab, PRO 140, 700 mg leronlimab
CytoDyn, Inc., Syneos Health
Metastatic Colorectal Cancer (mCRC)
06/28
08/28
NCT03838367: Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Active, not recruiting
1/2
48
US
350 mg leronlimab, PRO 140, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab
CytoDyn, Inc., Amarex Clinical Research
Triple Negative Breast Neoplasms
07/22
09/22
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

No Longer Available
N/A
US
PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
CytoDyn, Inc., Amarex Clinical Research
HIV
 
 
NCT04313075: A Compassionate Use Study of Leronlimab in Breast Cancer

No Longer Available
N/A
NA
Leronlimab, (PRO 140)
CytoDyn, Inc.
Metastatic Triple-Negative Breast Carcinoma
 
 
Relistor (methylnaltrexone bromide) / Ono Pharma, Bausch Health
ACTRN12611000002987: An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.

Not yet recruiting
4
6
 
The Royal Children's Hospital
Opioid-induced Constipation
 
 
2012-003409-86: The effect of medication to reduce opioid adverse events on oesophageal sensitivity in healthy volunteers.

Ongoing
4
10
Europe
Naloxone, methylnaltrexone, Concentrate for solution for infusion, Concentrate for cutaneous solution, Naloxon, Relistor
KULeuven, KULeuven
Altered oesophageal sensitivity, Altered oesophageal sensitivity, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
2009-017193-20: Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers.

Ongoing
4
20
Europe
Narcan, Relistor, Narcan, Relistor
UZLeuven
healthy volunteersnone; this is a physiological study to investigate the influence of opioid antagonism on gastric sensorimotor function
 
 
2010-020520-22: ESTUDIO PILOTO RANDOMIZADO ABIERTO DE AHORRO DE MEDIDAS RECTALES EN ESTREÑIMIENTO OPIOIDE EN POBLACIÓN EN FASE TERMINAL MEDIANTE EL EMPLEO DE METILNALTREXONA SUBCUTANEA

Ongoing
4
16
Europe
RELISTOR 12 mg/0,6 ml, solución inyectable, RELISTOR 12 mg/0,6 ml, solución inyectable
Fundación para la Investigación Biomédica del Hospital Gregorio Marañón
ESTREÑIMIENTO OPIOIDE
 
 
2010-020169-26: INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN.

Ongoing
4
20
Europe
NALOXONE HYDROCLORIDE, RELISTOR, V03AB15, A06AH01, NARCAN, RELISTOR, NARCAN, RELISTOR
healthy volunteersnone; this is a physiological study to investigate the influence of opioid antagonism on the interdigestive motor activity of the proximal gastrointestinal tract, hunger scores and plasma gastrointestinal hormone levels
 
 
2016-000532-17: Effect of impaired stomach relaxation on reflux Het effect van onvolledige maagrelaxatie op reflux

Ongoing
4
25
Europe
Relistor 12 mg/0,6 ml oplossing voor injectie, Concentrate for cutaneous solution, Relistor 12 mg/0,6 ml oplossing voor injectie
K.U. Leuven, K.U. Leuven
Impaired gastric accommodation Onvolledige maagaccommodatie, Impaired stomach relaxation Onvolledige maagrelaxatie, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
NCT03523520: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Completed
4
15
US
Methylnaltrexone Bromide 150 mg Oral Tablet, Relistor, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet, Movantik
University of Missouri-Columbia
Constipation Drug Induced
03/23
03/23
NCT06162377: Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Recruiting
4
25
US
Methylnaltrexone, Relistor™
M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma
12/25
12/25
2008-005692-10: A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related PainEstudio aleatorizado, en doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia de la metilnaltrexona subcutánea en el tratamiento del estreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral

Ongoing
3/4
36
Europe
Methylnaltrexone bromide for SC injection: 8 mg (0.4 mL, 20 mg/mL) in prefilled syringes, Methylnaltrexone bromide for SC injection: 12 mg (0.6 mL, 20 mg/mL) in prefilled syringes, Methylnaltrexone bromide for SC injection: (0.6 mL, 20 mg/mL) in vials, MOA-728,
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Opioid-induced constipation in subjects with cancer-related painEstreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral
 
 
ACTRN12611001182987: Does blocking the body's own morphine-like chemicals during exercise change the perception of breathlessness?

Recruiting
3
30
 
Flinders University- Deptment of Palliative and Supportive Services, Flinders Medical Centre foundation, Mundipharma Pty Ltd
Breathlessness during exercise in people with Chronic Obstructive Pulmonary Disease.
 
 
2008-005935-14: An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 forTreatment of Opioid-Induced Constipation in Subjects With Nonmalignant PainEstudio abierto para evaluar la seguridad a largo plazo de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno

Ongoing
3
72
Europe
Methylnaltrexone bromide for SC injection: 12 mg (0.6 mL, 20 mg/mL) in prefilled syringes, MOA-728,
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Opioid-induced constipation in subjects with non-malignant painTratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno
 
 
PAMORA-1, NCT04743570 / 2020-002313-18: Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis

Completed
2/3
105
Europe
Placebo treatment, Methylnaltrexone treatment
Asbjørn Mohr Drewes, Odense University Hospital, Hvidovre University Hospital, University Hospital Bispebjerg and Frederiksberg
Acute Pancreatitis
04/23
04/23
2004-004496-10: A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipation in patients undergoing elective orthopaedic surgery

Ongoing
2
36
Europe
Coated Methylnaltrexone, MNTX, Capsule, hard
Norgine International Limited
Coated MNTX is being developed for the prevention of constipation in patients taking opioids for hip and knee replacement surgery for analgesia (pain relief). This drug is as yet unlicensed for use in humans. Studies in subjects have shown no adverse effects of oral doses of MNTX, indicating that oral MNTX is safe and well tolerated in healthy humans at doses of up to 19.2mg/kg.
 
 
NCT04787848: Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Recruiting
N/A
200
US
Relistor Injectable Product, Methylnaltrexone Bromide
Florida International University
Chronic Widespread Pain
11/25
12/25
Azedra (iobenguane I 131) / Lantheus
NCT03126916: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Active, not recruiting
3
724
Canada, US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Dexrazoxane Hydrochloride, Cardioxane, Totect, Zinecard, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Iobenguane I-123, AdreView, iobenguane I 123, Iobenguane I-131, (131)I-MIBG, 131I-MIBG, I 131 Meta-iodobenzylguanidine, I-131 Metaiodobenzylguanidine, Iobenguane (131I), Iobenguane I 131, Iodine I 131 Metaiodobenzylguanidine, MIBG I-131, Raiatt MIBG-I 131, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, Lorviqua, PF 06463922, PF-06463922, PF06463922, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Melphalan Hydrochloride, Alkeran, Alkerana, Evomela, Hepzato, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Therapeutic Conventional Surgery, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Neuroblastoma
09/26
09/26
2007-007974-45: A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.

Ongoing
2
31
Europe
gemcitabine,
AMC, KIKA
relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 years
 
 
OPTIMUM, NCT03561259: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Recruiting
2
60
US
131I-MIBG, I-131 meta-iodobenzylguanidine, Iobenguane I-131 MIBG Injection, 131-MIBG + Vorinostat
Jubilant DraxImage Inc.
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
12/23
04/25
MIBG, NCT02378428: Therapy for Patients With Avid Tumors

Active, not recruiting
2
65
US
MIBG, <131>I-Metaiodobenzylguanidine
Nationwide Children's Hospital
MIBG Avid Tumors
12/25
12/25
NCT00107289: Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Recruiting
2
200
US
iobenguane I 131
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Neuroblastoma, Pheochromocytoma
05/26
05/26
SPORE-3, NCT04614766: A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Withdrawn
1/2
50
US
Lutathera, lutetium Lu 177 dotatate, Azedra, iobenguane I-131
David Bushnell, National Institutes of Health (NIH), National Cancer Institute (NCI), Progenics Pharmaceuticals, Inc.
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
04/24
04/24
NCT01175356: Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Active, not recruiting
1
99
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, in vitro-treated PBPC transplantation, in vitro-treated peripheral blood progenitor cell transplantation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Iobenguane I-131, (131)I-MIBG, 131I-MIBG, I 131 Meta-iodobenzylguanidine, I-131 Metaiodobenzylguanidine, Iobenguane (131I), Iobenguane I 131, Iodine I 131 Metaiodobenzylguanidine, MIBG I-131, Raiatt MIBG-I 131, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
09/16
09/25
NCT03332667: MIBG With Dinutuximab +/- Vorinostat

Completed
1
45
US
131I-MIBG, 131I-Metaiodobenzylguanidine, Iobenguane sulfate, m-Iodobenzylguanidine sulfate, MIBG, Dinutuximab, Chimeric Monoclonal Antibody 14.18, MAB Ch 14.18, Unituxin, Ch14.18, Vorinostat, Zolina, Sargramostim, Potassium Iodide
New Approaches to Neuroblastoma Therapy Consortium, United Therapeutics, National Cancer Institute (NCI)
Neuroblastoma
02/24
02/24
Inbraced, NCT02914405 / 2016-002221-11: Phase I Study of 131-I MIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children with Relapsed/refractory Neuroblastoma

Active, not recruiting
1
44
Europe, US
Nivolumab, BMS-936558, MDX1106, ONO-4538, anti-PD-1) NSC#748726, IND #124729, Ch14.18/CHO, Mouse-human chimeric monoclonal anti-GD2 Immunoglobulin G1 (IgG1) antibody
University Hospital Southampton NHS Foundation Trust, University College London Hospitals, University of Wisconsin, Madison, University Hospital Greifswald, Solving Kids' Cancer US/EU, Joining Against Cancer in Kids, The Band of Parents
Neuroblastoma
05/25
07/25
NCT03044977: Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Active, not recruiting
1
20
US
90Y-DOTA-3-Tyr-Octreotide, 90Y DOTATOC, 131I-MIBG
David Bushnell, National Institutes of Health (NIH), National Cancer Institute (NCI), Holden Comprehensive Cancer Center
Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
12/25
12/27
NCT06669481: Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics

Completed
N/A
159
RoW
Semiquantitative 131I-MIBG Scintigraphy Assessment
Peking Union Medical College Hospital
Pheochromocytoma, Paraganglioma
04/23
04/23
ChiCTR1800015757: Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease

Not yet recruiting
N/A
 
Tongji hospital, Tongji University; Tongji hospital, Tongji University, Special fund
Parkinson's Disease
 
 
NCT03649438: 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

No Longer Available
N/A
US
131 I-Metaiodobenzylguanidine, 131I-MIBG, Potassium Iodide, KI solution, G-csf, Neulasta
University of Texas Southwestern Medical Center
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
 
 
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT03015844: A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Available
N/A
US
131-I-meta-iodobenzylguanidine, 131I-MIBG, Iobenguane
Northwell Health, Cohen Children's Medical Center
Neuroblastoma, Pheochromocytoma
 
 
NCT01370330: 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Available
N/A
US
Metaiodobenzylguanidine (MIBG), 131I-MIBG
Kieuhoa Vo, Cannonball Kids' Cancer Foundation
Neuroblastoma
 
 
NCT01163383: 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Available
N/A
US
131 I-Metaiodobenzylguanidine (131 I-MIBG), MIBG, 131 I-Metaiodobenzylguanidine, radioactive Iodine (131), Metaiodobenzylguanidine, 131 I-MIBG, 131 I- Metaidobenzylguanidine, Radioactive iodine, Metaiodobenzylguanidine therapy
John Maris
Neuroblastoma, Childhood Metastatic Pheochromocytoma
 
 
NCT01838187: Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

No Longer Available
N/A
US
I-131 MIBG, ◦I-131 Iobenguane, ◦I-131 meta-iodobenzylguanidine, Vorinostat, SAHA (suberanilohydroxamic acid), Zolinza
Children's Hospital Medical Center, Cincinnati
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT06000787: MCT for the Harvard/UCSF ROBIN Center

Recruiting
N/A
47
US
External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG)
Brigham and Women's Hospital, Dana-Farber Cancer Institute, National Cancer Institute (NCI), University of California, San Francisco
Glioma, Childhood Brainstem, Neuroblastoma
08/28
08/28
LNTH-1095 / Lantheus
ARROW, NCT03939689: Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Active, not recruiting
2
120
Canada, US
I-131-1095, Enzalutamide, Xtandi
Progenics Pharmaceuticals, Inc.
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
09/23
09/24
lutetium zadavotide guraxetan (PNT2002) / Lantheus
2021-002641-15: To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPC

Not yet recruiting
3
390
Europe
177Lu-PNT2002, 68Ga-PSMA-11 prepared using PSMA-11 sterile kit, Abiraterone, Enzalutamide, 177Lu-PNT2002, Solution for injection, Film-coated tablet, Zytiga, Xtandi, GalliaPharm
Point BioPharma Inc., Point BioPharma
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate cancer, Diseases [C] - Cancer [C04]
 
 
SPLASH, NCT04647526: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Checkmark Efficacy and safety data from SPLASH trial for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Efficacy and safety data from SPLASH trial for mCRPC at ESMO 2022
Checkmark Efficacy and safety data from the lead-in cohort of the SPLASH trial in mCRPC
Sep 2022 - Sep 2022: Efficacy and safety data from the lead-in cohort of the SPLASH trial in mCRPC
Active, not recruiting
3
415
Europe, Canada, US
[Lu-177]-PNT2002, [Lu-177]-PSMA-I&T, Abiraterone, Enzalutamide
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Metastatic Castration-Resistant Prostate Cancer
11/23
03/28
ROADSTER, NCT05230251: Radioligand fOr locAl raDiorecurrent proStaTe cancER

Active, not recruiting
2
12
Canada
177Lu-PNT2002, [Lu-177]-PNT2002 Injection, High Dose Radiation
Glenn Bauman, London Health Sciences Foundation
Prostate Cancer
09/23
12/24
LUNAR, NCT05496959: 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The Study

Active, not recruiting
2
93
US
Lutetium Lu-177 PNT2002, 177Lu-labeled PNT2002, 177Lu-PNT2002, [Lu-177]-PNT2002, [Lu-177]-PSMA-I and T, Lu177-PNT2002, Lutetium Lu-177-PNT2002, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Jonsson Comprehensive Cancer Center, Eli Lilly and Company
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
09/32
09/33
NCT06322576: 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Recruiting
2
10
US
177Lu-PNT2002, 177Lu PSMA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adenoid Cystic Carcinoma Research Foundation, Progenics Pharmaceuticals, Inc.
Adenoid Cystic Carcinoma
03/30
02/35
NCT04886986: Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Suspended
1/2
48
US
225Ac-J591, 177Lu-PSMA-I&T, 177Lu-PNT2002, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC
Weill Medical College of Cornell University, POINT Biopharma
Prostate Cancer
12/26
12/27
NCT06361810: PSMA Therapy and Immunotherapy in Kidney Cancer

Not yet recruiting
1/2
37
NA
Pembrolizumab, Keytruda, 177Lu-PNT2002, 177Lu-PSMA I&T, (F-18)-DCFPyL, Pylarify
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Lantheus Medical Imaging
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
01/31
01/32
NCT06033001: Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Temporarily Not Available
N/A
US
[Lu-177]-PNT2002
Lantheus Medical Imaging, Eli Lilly and Company
Castration-Resistant Prostatic Cancer
 
 
lutetium-177 Octreotate (PNT2003) / Lantheus, Eli Lilly
NCT02743741: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Active, not recruiting
N/A
195
Canada
Lutetium-177 Octreotate, Lu-DOTATATE, [Lu-177]-DOTATATE
University Health Network, Toronto, Ozmosis Research Inc., Cancer Care Ontario, Canadian Molecular Imaging Probe Consortium
Neuroendocrine Tumors
06/26
06/26
VMT-?-NET / Perspective Therap
NCT06427798: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Recruiting
1/2
66
US
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
National Cancer Institute (NCI)
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
07/29
07/39
212-Pb-VMT, NCT05636618: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Recruiting
1/2
280
US
[212Pb]VMT-α-NET
Perspective Therapeutics
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Tumor Carcinoid, Carcinoid Tumor of GI System, Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Small-cell Lung Cancer
11/29
12/29
NCT06148636: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Active, not recruiting
1
24
US
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
David Bushnell, Holden Comprehensive Cancer Center, National Cancer Institute (NCI), Perspective Therapeutics
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
11/26
11/27
NCT05111509: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Enrolling by invitation
1
20
US
[203Pb]VMT-α-NET, SPECT/CT
Yusuf Menda, Perspective Therapeutics, Holden Comprehensive Cancer Center, National Cancer Institute (NCI)
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
09/25
12/25
NCT06479811: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Not yet recruiting
1
120
US
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
National Cancer Institute (NCI)
Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Gastrointestinal Neuroendocrine Tumors, Somatostatin Receptor Positive
01/29
01/32
RAD 502 / Lantheus
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
2020-001996-33: A Phase 2b/3 Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Not yet recruiting
3
290
Europe
Leronlimab(PRO 140), Injection, Leronlimab Injection 175mg/ml (PRO-140)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019 (COVID-19), Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT02859961: Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection

Completed
2/3
556
US
PRO 140 (350 mg), Leronlimab, PRO 140 (525 mg), PRO 140 (700 mg)
CytoDyn, Inc.
HIV
09/20
12/20
NCT02990858: An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

Active, not recruiting
2/3
44
NA
PRO 140 SC injections
CytoDyn, Inc.
Hiv, Human Immunodeficiency Virus
06/22
08/22
NCT03902522: PRO 140 in Treatment-Experienced HIV-1 Subjects

Active, not recruiting
2/3
25
US
PRO 140, Leronlimab
CytoDyn, Inc.
HIV-1-infection
07/22
08/22
PRO 140_CD03 Extension, NCT05271370: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Active, not recruiting
2/3
56
US
PRO 140 350, PRO 140 525, PRO 140 700
CytoDyn, Inc.
HIV-1-infection
12/22
04/23
NCT04347239 / 2020-001996-33: Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Active, not recruiting
2b
394
US
Placebos, Leronlimab (700mg)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019
10/21
06/22
NCT04504942: Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
2
30
US
Leronlimab
CytoDyn, Inc., Amarex Clinical Research
Solid Tumor, Adult
11/21
07/22
NCT04521114: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Completed
2
87
US
Placebo, leronlimab 700 mg, PRO 140, leronlimab 350 mg
CytoDyn, Inc., Amarex Clinical Research
Nonalcoholic Steatohepatitis (NASH)
12/21
12/21
NCT02355184: An Extension of Protocol PRO 140_CD01 TS Study

Active, not recruiting
2
28
US
PRO 140 350mg weekly SQ injection., PRO 140
CytoDyn, Inc.
HIV, Human Immunodeficiency Virus
06/22
08/22
NCT05730673: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Withdrawn
2
NA
700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2, 160 mg Regorafenib at week 3
CytoDyn, Inc., Amarex Clinical Research
CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer
05/23
08/23
NCT06699836: A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Recruiting
2
60
US
350 mg leronlimab, PRO 140, 700 mg leronlimab
CytoDyn, Inc., Syneos Health
Metastatic Colorectal Cancer (mCRC)
06/28
08/28
NCT03838367: Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Active, not recruiting
1/2
48
US
350 mg leronlimab, PRO 140, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab
CytoDyn, Inc., Amarex Clinical Research
Triple Negative Breast Neoplasms
07/22
09/22
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

No Longer Available
N/A
US
PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
CytoDyn, Inc., Amarex Clinical Research
HIV
 
 
NCT04313075: A Compassionate Use Study of Leronlimab in Breast Cancer

No Longer Available
N/A
NA
Leronlimab, (PRO 140)
CytoDyn, Inc.
Metastatic Triple-Negative Breast Carcinoma
 
 
Relistor (methylnaltrexone bromide) / Ono Pharma, Bausch Health
ACTRN12611000002987: An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.

Not yet recruiting
4
6
 
The Royal Children's Hospital
Opioid-induced Constipation
 
 
2012-003409-86: The effect of medication to reduce opioid adverse events on oesophageal sensitivity in healthy volunteers.

Ongoing
4
10
Europe
Naloxone, methylnaltrexone, Concentrate for solution for infusion, Concentrate for cutaneous solution, Naloxon, Relistor
KULeuven, KULeuven
Altered oesophageal sensitivity, Altered oesophageal sensitivity, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
2009-017193-20: Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers.

Ongoing
4
20
Europe
Narcan, Relistor, Narcan, Relistor
UZLeuven
healthy volunteersnone; this is a physiological study to investigate the influence of opioid antagonism on gastric sensorimotor function
 
 
2010-020520-22: ESTUDIO PILOTO RANDOMIZADO ABIERTO DE AHORRO DE MEDIDAS RECTALES EN ESTREÑIMIENTO OPIOIDE EN POBLACIÓN EN FASE TERMINAL MEDIANTE EL EMPLEO DE METILNALTREXONA SUBCUTANEA

Ongoing
4
16
Europe
RELISTOR 12 mg/0,6 ml, solución inyectable, RELISTOR 12 mg/0,6 ml, solución inyectable
Fundación para la Investigación Biomédica del Hospital Gregorio Marañón
ESTREÑIMIENTO OPIOIDE
 
 
2010-020169-26: INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN.

Ongoing
4
20
Europe
NALOXONE HYDROCLORIDE, RELISTOR, V03AB15, A06AH01, NARCAN, RELISTOR, NARCAN, RELISTOR
healthy volunteersnone; this is a physiological study to investigate the influence of opioid antagonism on the interdigestive motor activity of the proximal gastrointestinal tract, hunger scores and plasma gastrointestinal hormone levels
 
 
2016-000532-17: Effect of impaired stomach relaxation on reflux Het effect van onvolledige maagrelaxatie op reflux

Ongoing
4
25
Europe
Relistor 12 mg/0,6 ml oplossing voor injectie, Concentrate for cutaneous solution, Relistor 12 mg/0,6 ml oplossing voor injectie
K.U. Leuven, K.U. Leuven
Impaired gastric accommodation Onvolledige maagaccommodatie, Impaired stomach relaxation Onvolledige maagrelaxatie, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
NCT03523520: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Completed
4
15
US
Methylnaltrexone Bromide 150 mg Oral Tablet, Relistor, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet, Movantik
University of Missouri-Columbia
Constipation Drug Induced
03/23
03/23
NCT06162377: Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Recruiting
4
25
US
Methylnaltrexone, Relistor™
M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma
12/25
12/25
2008-005692-10: A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related PainEstudio aleatorizado, en doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia de la metilnaltrexona subcutánea en el tratamiento del estreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral

Ongoing
3/4
36
Europe
Methylnaltrexone bromide for SC injection: 8 mg (0.4 mL, 20 mg/mL) in prefilled syringes, Methylnaltrexone bromide for SC injection: 12 mg (0.6 mL, 20 mg/mL) in prefilled syringes, Methylnaltrexone bromide for SC injection: (0.6 mL, 20 mg/mL) in vials, MOA-728,
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Opioid-induced constipation in subjects with cancer-related painEstreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral
 
 
ACTRN12611001182987: Does blocking the body's own morphine-like chemicals during exercise change the perception of breathlessness?

Recruiting
3
30
 
Flinders University- Deptment of Palliative and Supportive Services, Flinders Medical Centre foundation, Mundipharma Pty Ltd
Breathlessness during exercise in people with Chronic Obstructive Pulmonary Disease.
 
 
2008-005935-14: An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 forTreatment of Opioid-Induced Constipation in Subjects With Nonmalignant PainEstudio abierto para evaluar la seguridad a largo plazo de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno

Ongoing
3
72
Europe
Methylnaltrexone bromide for SC injection: 12 mg (0.6 mL, 20 mg/mL) in prefilled syringes, MOA-728,
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Opioid-induced constipation in subjects with non-malignant painTratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno
 
 
PAMORA-1, NCT04743570 / 2020-002313-18: Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis

Completed
2/3
105
Europe
Placebo treatment, Methylnaltrexone treatment
Asbjørn Mohr Drewes, Odense University Hospital, Hvidovre University Hospital, University Hospital Bispebjerg and Frederiksberg
Acute Pancreatitis
04/23
04/23
2004-004496-10: A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipation in patients undergoing elective orthopaedic surgery

Ongoing
2
36
Europe
Coated Methylnaltrexone, MNTX, Capsule, hard
Norgine International Limited
Coated MNTX is being developed for the prevention of constipation in patients taking opioids for hip and knee replacement surgery for analgesia (pain relief). This drug is as yet unlicensed for use in humans. Studies in subjects have shown no adverse effects of oral doses of MNTX, indicating that oral MNTX is safe and well tolerated in healthy humans at doses of up to 19.2mg/kg.
 
 
NCT04787848: Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Recruiting
N/A
200
US
Relistor Injectable Product, Methylnaltrexone Bromide
Florida International University
Chronic Widespread Pain
11/25
12/25
Azedra (iobenguane I 131) / Lantheus
NCT03126916: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Active, not recruiting
3
724
Canada, US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Dexrazoxane Hydrochloride, Cardioxane, Totect, Zinecard, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Iobenguane I-123, AdreView, iobenguane I 123, Iobenguane I-131, (131)I-MIBG, 131I-MIBG, I 131 Meta-iodobenzylguanidine, I-131 Metaiodobenzylguanidine, Iobenguane (131I), Iobenguane I 131, Iodine I 131 Metaiodobenzylguanidine, MIBG I-131, Raiatt MIBG-I 131, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, Lorviqua, PF 06463922, PF-06463922, PF06463922, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Melphalan Hydrochloride, Alkeran, Alkerana, Evomela, Hepzato, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Therapeutic Conventional Surgery, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Neuroblastoma
09/26
09/26
2007-007974-45: A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.

Ongoing
2
31
Europe
gemcitabine,
AMC, KIKA
relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 years
 
 
OPTIMUM, NCT03561259: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Recruiting
2
60
US
131I-MIBG, I-131 meta-iodobenzylguanidine, Iobenguane I-131 MIBG Injection, 131-MIBG + Vorinostat
Jubilant DraxImage Inc.
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
12/23
04/25
MIBG, NCT02378428: Therapy for Patients With Avid Tumors

Active, not recruiting
2
65
US
MIBG, <131>I-Metaiodobenzylguanidine
Nationwide Children's Hospital
MIBG Avid Tumors
12/25
12/25
NCT00107289: Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Recruiting
2
200
US
iobenguane I 131
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Neuroblastoma, Pheochromocytoma
05/26
05/26
SPORE-3, NCT04614766: A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Withdrawn
1/2
50
US
Lutathera, lutetium Lu 177 dotatate, Azedra, iobenguane I-131
David Bushnell, National Institutes of Health (NIH), National Cancer Institute (NCI), Progenics Pharmaceuticals, Inc.
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
04/24
04/24
NCT01175356: Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Active, not recruiting
1
99
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, in vitro-treated PBPC transplantation, in vitro-treated peripheral blood progenitor cell transplantation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Iobenguane I-131, (131)I-MIBG, 131I-MIBG, I 131 Meta-iodobenzylguanidine, I-131 Metaiodobenzylguanidine, Iobenguane (131I), Iobenguane I 131, Iodine I 131 Metaiodobenzylguanidine, MIBG I-131, Raiatt MIBG-I 131, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
09/16
09/25
NCT03332667: MIBG With Dinutuximab +/- Vorinostat

Completed
1
45
US
131I-MIBG, 131I-Metaiodobenzylguanidine, Iobenguane sulfate, m-Iodobenzylguanidine sulfate, MIBG, Dinutuximab, Chimeric Monoclonal Antibody 14.18, MAB Ch 14.18, Unituxin, Ch14.18, Vorinostat, Zolina, Sargramostim, Potassium Iodide
New Approaches to Neuroblastoma Therapy Consortium, United Therapeutics, National Cancer Institute (NCI)
Neuroblastoma
02/24
02/24
Inbraced, NCT02914405 / 2016-002221-11: Phase I Study of 131-I MIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children with Relapsed/refractory Neuroblastoma

Active, not recruiting
1
44
Europe, US
Nivolumab, BMS-936558, MDX1106, ONO-4538, anti-PD-1) NSC#748726, IND #124729, Ch14.18/CHO, Mouse-human chimeric monoclonal anti-GD2 Immunoglobulin G1 (IgG1) antibody
University Hospital Southampton NHS Foundation Trust, University College London Hospitals, University of Wisconsin, Madison, University Hospital Greifswald, Solving Kids' Cancer US/EU, Joining Against Cancer in Kids, The Band of Parents
Neuroblastoma
05/25
07/25
NCT03044977: Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Active, not recruiting
1
20
US
90Y-DOTA-3-Tyr-Octreotide, 90Y DOTATOC, 131I-MIBG
David Bushnell, National Institutes of Health (NIH), National Cancer Institute (NCI), Holden Comprehensive Cancer Center
Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
12/25
12/27
NCT06669481: Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics

Completed
N/A
159
RoW
Semiquantitative 131I-MIBG Scintigraphy Assessment
Peking Union Medical College Hospital
Pheochromocytoma, Paraganglioma
04/23
04/23
ChiCTR1800015757: Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease

Not yet recruiting
N/A
 
Tongji hospital, Tongji University; Tongji hospital, Tongji University, Special fund
Parkinson's Disease
 
 
NCT03649438: 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

No Longer Available
N/A
US
131 I-Metaiodobenzylguanidine, 131I-MIBG, Potassium Iodide, KI solution, G-csf, Neulasta
University of Texas Southwestern Medical Center
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
 
 
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT03015844: A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Available
N/A
US
131-I-meta-iodobenzylguanidine, 131I-MIBG, Iobenguane
Northwell Health, Cohen Children's Medical Center
Neuroblastoma, Pheochromocytoma
 
 
NCT01370330: 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Available
N/A
US
Metaiodobenzylguanidine (MIBG), 131I-MIBG
Kieuhoa Vo, Cannonball Kids' Cancer Foundation
Neuroblastoma
 
 
NCT01163383: 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Available
N/A
US
131 I-Metaiodobenzylguanidine (131 I-MIBG), MIBG, 131 I-Metaiodobenzylguanidine, radioactive Iodine (131), Metaiodobenzylguanidine, 131 I-MIBG, 131 I- Metaidobenzylguanidine, Radioactive iodine, Metaiodobenzylguanidine therapy
John Maris
Neuroblastoma, Childhood Metastatic Pheochromocytoma
 
 
NCT01838187: Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

No Longer Available
N/A
US
I-131 MIBG, ◦I-131 Iobenguane, ◦I-131 meta-iodobenzylguanidine, Vorinostat, SAHA (suberanilohydroxamic acid), Zolinza
Children's Hospital Medical Center, Cincinnati
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT06000787: MCT for the Harvard/UCSF ROBIN Center

Recruiting
N/A
47
US
External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG)
Brigham and Women's Hospital, Dana-Farber Cancer Institute, National Cancer Institute (NCI), University of California, San Francisco
Glioma, Childhood Brainstem, Neuroblastoma
08/28
08/28
LNTH-1095 / Lantheus
ARROW, NCT03939689: Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Active, not recruiting
2
120
Canada, US
I-131-1095, Enzalutamide, Xtandi
Progenics Pharmaceuticals, Inc.
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
09/23
09/24
lutetium zadavotide guraxetan (PNT2002) / Lantheus
2021-002641-15: To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPC

Not yet recruiting
3
390
Europe
177Lu-PNT2002, 68Ga-PSMA-11 prepared using PSMA-11 sterile kit, Abiraterone, Enzalutamide, 177Lu-PNT2002, Solution for injection, Film-coated tablet, Zytiga, Xtandi, GalliaPharm
Point BioPharma Inc., Point BioPharma
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate cancer, Diseases [C] - Cancer [C04]
 
 
SPLASH, NCT04647526: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Checkmark Efficacy and safety data from SPLASH trial for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Efficacy and safety data from SPLASH trial for mCRPC at ESMO 2022
Checkmark Efficacy and safety data from the lead-in cohort of the SPLASH trial in mCRPC
Sep 2022 - Sep 2022: Efficacy and safety data from the lead-in cohort of the SPLASH trial in mCRPC
Active, not recruiting
3
415
Europe, Canada, US
[Lu-177]-PNT2002, [Lu-177]-PSMA-I&T, Abiraterone, Enzalutamide
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Metastatic Castration-Resistant Prostate Cancer
11/23
03/28
ROADSTER, NCT05230251: Radioligand fOr locAl raDiorecurrent proStaTe cancER

Active, not recruiting
2
12
Canada
177Lu-PNT2002, [Lu-177]-PNT2002 Injection, High Dose Radiation
Glenn Bauman, London Health Sciences Foundation
Prostate Cancer
09/23
12/24
LUNAR, NCT05496959: 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The Study

Active, not recruiting
2
93
US
Lutetium Lu-177 PNT2002, 177Lu-labeled PNT2002, 177Lu-PNT2002, [Lu-177]-PNT2002, [Lu-177]-PSMA-I and T, Lu177-PNT2002, Lutetium Lu-177-PNT2002, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Jonsson Comprehensive Cancer Center, Eli Lilly and Company
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
09/32
09/33
NCT06322576: 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Recruiting
2
10
US
177Lu-PNT2002, 177Lu PSMA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adenoid Cystic Carcinoma Research Foundation, Progenics Pharmaceuticals, Inc.
Adenoid Cystic Carcinoma
03/30
02/35
NCT04886986: Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Suspended
1/2
48
US
225Ac-J591, 177Lu-PSMA-I&T, 177Lu-PNT2002, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC
Weill Medical College of Cornell University, POINT Biopharma
Prostate Cancer
12/26
12/27
NCT06361810: PSMA Therapy and Immunotherapy in Kidney Cancer

Not yet recruiting
1/2
37
NA
Pembrolizumab, Keytruda, 177Lu-PNT2002, 177Lu-PSMA I&T, (F-18)-DCFPyL, Pylarify
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Lantheus Medical Imaging
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
01/31
01/32
NCT06033001: Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Temporarily Not Available
N/A
US
[Lu-177]-PNT2002
Lantheus Medical Imaging, Eli Lilly and Company
Castration-Resistant Prostatic Cancer
 
 
lutetium-177 Octreotate (PNT2003) / Lantheus, Eli Lilly
NCT02743741: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Active, not recruiting
N/A
195
Canada
Lutetium-177 Octreotate, Lu-DOTATATE, [Lu-177]-DOTATATE
University Health Network, Toronto, Ozmosis Research Inc., Cancer Care Ontario, Canadian Molecular Imaging Probe Consortium
Neuroendocrine Tumors
06/26
06/26
VMT-?-NET / Perspective Therap
NCT06427798: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Recruiting
1/2
66
US
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
National Cancer Institute (NCI)
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
07/29
07/39
212-Pb-VMT, NCT05636618: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Recruiting
1/2
280
US
[212Pb]VMT-α-NET
Perspective Therapeutics
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Tumor Carcinoid, Carcinoid Tumor of GI System, Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Small-cell Lung Cancer
11/29
12/29
NCT06148636: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Active, not recruiting
1
24
US
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
David Bushnell, Holden Comprehensive Cancer Center, National Cancer Institute (NCI), Perspective Therapeutics
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
11/26
11/27
NCT05111509: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Enrolling by invitation
1
20
US
[203Pb]VMT-α-NET, SPECT/CT
Yusuf Menda, Perspective Therapeutics, Holden Comprehensive Cancer Center, National Cancer Institute (NCI)
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
09/25
12/25
NCT06479811: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Not yet recruiting
1
120
US
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
National Cancer Institute (NCI)
Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Gastrointestinal Neuroendocrine Tumors, Somatostatin Receptor Positive
01/29
01/32
RAD 502 / Lantheus
No trials found

Download Options